Pharmacokinetics of HM-3 After Intravitreal Administration in Mice

Abstract Purpose: HM-3, an RGD-modified endostatin-derived polypeptide, is a potent angiogenesis inhibitor synthesized in our laboratory. This study investigated the HM-3 pharmacokinetics of intravitreally administered in mice eyes as an anti-angiogenesis drug for age-related macular degeneration. Materials and methods: A total of 288 C57BL/6J mice were evaluated and divided into four groups. Each mouse in different groups received single bilateral intravitreal injection with HM-3. The concentrations of HM-3 in choroid/sclera, retina and serum were determined by indirect competitive enzyme-linked immunosorbent assay. Results: After intravitreal administration of doses of 0, 10, 20 and 40 μg/eye HM-3, the observed maximum concentration (Cmax) was 12.98 ± 1.42, 27.87 ± 3.64 and 55.96 ± 11.94 ng/mg, respectively; and the total area under the curve (AUCtot) was 739.23 ± 190.32, 1171.74 ± 528.75 and 1777.71 ± 511.64 h ng/mg; the elimination half-life (T1/2) in retina was 104.85 ± 36.90, 107.42 ± 35.25 and 101.12 ± 15.82 h; the mean residence time (MRT) was 172.46 ± 63.80, 164.70 ± 52.72 and 181.32 ± 26.01 h, respectively. In choroid/sclera, the Cmax was 5.29 ± 0.34, 6.29 ± 1.87 and 8.14 ± 0.71 ng/mg, respectively; AUCtot was 579.03 ± 56.50, 762.20 ± 201.09 and 720.91 ±243.87 h ng/mg; T1/2 was 54.04 ± 25.99, 59.33 ± 24.46 and 47.10 ± 10.00 h, respectively; MRT was 139.98 ± 23.93, 155.43 ± 17.81 and 136.45 ± 18.17 h, respectively. But in serum, the Cmax was 482.00 ± 38.97, 493.94 ± 97.64 and 1033.10 ± 276.33 ng/ml, respectively; AUCtot was 21128.55 ± 4683.68, 53444.57 ± 16963.99 and 53164.84 ±1535.06 h ng/ml; T1/2 was 48.39 ± 14.89, 47.96 ± 12.97 and 49.98 ± 30.07 h, respectively; MRT was 108.6 ± 47.17, 159.76 ± 18.82 and 125.33 ± 21.41 h, respectively. Conclusions: The pharmacokinetic profiles of intravitreal administration HM-3 provide the basis for the development of reasonable dosing regimens of clinical choroidal neovascularization (CNV) treatment. However, the vitreous and blood retinal barrier might be barriers to drug distribution and diffusion. In addition, fluid flow for the anterior transport and choroidal blood circulation might play important roles for multiple peaking. Carrying out the research into pharmacokinetics of HM-3 provides the information for laying down drug delivery scheme in mice model of CNV.

[1]  Y. Akova,et al.  Structural consequences after intravitreal bevacizumab injection without increasing apoptotic cell death in a retinopathy of prematurity mouse model , 2012, Acta ophthalmologica.

[2]  Chi Zhang,et al.  In vivo pharmacokinetics, immunogenicity and mechanism of PEGylated antitumor polypeptide. , 2012, Current pharmaceutical design.

[3]  S. Chemtob,et al.  Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration. , 2012, Investigative ophthalmology & visual science.

[4]  Johanna M Seddon,et al.  Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. , 2011, Ophthalmology.

[5]  A. Bird,et al.  Long-term visual outcome of pigment epithelial tears in association with anti-VEGF therapy of pigment epithelial detachment in AMD , 2011, Eye.

[6]  P. Mitchell.  A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab , 2011, Current medical research and opinion.

[7]  Han-mei Xu,et al.  Site-specific modification of anti-angiogenesis peptide HM-3 by polyethylene glycol molecular weight of 20 kDa. , 2010, Journal of biochemistry.

[8]  S. Garg,et al.  Complications of intravitreal injections , 2010, Current opinion in ophthalmology.

[9]  M. Tolentino.  Current molecular understanding and future treatment strategies for pathologic ocular neovascularization. , 2009, Current molecular medicine.

[10]  J. Olson,et al.  VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration , 2009, Expert opinion on investigational drugs.

[11]  Tao Xi,et al.  Studies of poly(ethylene glycol) modification of HM-3 polypeptides. , 2009, Bioconjugate chemistry.

[12]  D. Livant,et al.  α5β1 Integrin Ligand PHSRN Induces Invasion and α5 mRNA in Endothelial Cells to Stimulate Angiogenesis , 2009 .

[13]  Min Wang,et al.  An RGD-modified endostatin-derived synthetic peptide shows antitumor activity in vivo. , 2008, Bioconjugate chemistry.

[14]  Salvatore Grisanti,et al.  The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration , 2008, Progress in Retinal and Eye Research.

[15]  H. Kessler,et al.  Rational Design of Highly Active and Selective Ligands for the α5β1 Integrin Receptor , 2008, Chembiochem : a European journal of chemical biology.

[16]  W. Green,et al.  Safety of Intravitreal Ketorolac and Diclofenac: An Electroretinographic and Histopathologic Study , 2008, Retina.

[17]  S. Mousa,et al.  Studies with an Orally Bioavailable αV Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.

[18]  P. Heiduschka,et al.  Penetration of bevacizumab through the retina after intravitreal injection in the monkey. , 2007, Investigative ophthalmology & visual science.

[19]  A. Joussen,et al.  Varied expression of functionally important genes of RPE and choroid in the macula and in the periphery of normal human eyes , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.

[20]  K. Braeckmans,et al.  Vitreous: a barrier to nonviral ocular gene therapy. , 2005, Investigative ophthalmology & visual science.

[21]  Rupak K Banerjee,et al.  Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[22]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[23]  A. Urtti,et al.  Neural retina limits the nonviral gene transfer to retinal pigment epithelium in an in vitro bovine eye model , 2004, The AAPS Journal.

[24]  B. Schlosshauer,et al.  In vitro model of the outer blood-retina barrier. , 2004, Brain research. Brain research protocols.

[25]  J. Cunha-Vaz.  The blood-retinal barriers system. Basic concepts and clinical evaluation. , 2004, Experimental eye research.

[26]  P. Missel.  Hydraulic Flow and Vascular Clearance Influences on Intravitreal Drug Delivery , 2002, Pharmaceutical Research.

[27]  A. Lang,et al.  Long-term follow-up of unilateral pallidotomy in advanced Parkinson's disease. , 2000, The New England journal of medicine.

[28]  S. Heegaard,et al.  Structure and composition of the inner limiting membrane of the retina , 1986, Graefe's Archive for Clinical and Experimental Ophthalmology.

[29]  W. Foulds,et al.  Effect of intravitreal hyaluronidase on the clearance of tritiated water from the vitreous to the choroid. , 1985, The British journal of ophthalmology.

[30]  Tien Yin Wong,et al.  Ophthalmology 1 Age-related macular degeneration , 2012 .

[31]  Xu Han-mei.  Research of McAb-Based Competitive ELISA for Detecting HM-3 Residues in Serum , 2010 .

[32]  D. Livant,et al.  alpha(5)beta(1) Integrin Ligand PHSRN Induces Invasion and alpha(5) mRNA in Endothelial Cells to Stimulate Angiogenesis. , 2009, Translational oncology.

[33]  Jing Xu,et al.  Permeability and Diffusion in Vitreous Humor: Implications for Drug Delivery , 2004, Pharmaceutical Research.

[34]  J W Berger,et al.  Age-related macular degeneration. , 2000, The New England journal of medicine.

[35]  B. Saville,et al.  Drug distribution in the vitreous humor of the human eye: the effects of intravitreal injection position and volume. , 1997, Current eye research.